Table 2

Clinical Characteristics of Patients With or Without Hyperglycemia

With Hyperglycemia (≥160 mg/dl)Without Hyperglycemia (<160 mg/dl)p Value
No. of patients7571
Age (yrs)61 ± 1058 ± 110.10
Gender (male/female)57/1859/120.28
Peak creatine kinase (IU/l)2,497 ± 1,6031,804 ± 1,3000.005
No reflow on MCE (%)52.014.1< 0.0001
Blood glucose (mg/dl)221 ± 69128 ± 18< 0.0001
HbA1c(%)6.2 ± 1.65.1 ± 0.5< 0.0001
Total cholesterol (mg/dl)194 ± 45204 ± 450.23
Triglycerides (mg/dl)109 ± 103117 ± 780.59
Risk factors (%)
Diabetes mellitus45.39.9< 0.0001
Hypertension49.350.70.86
Hyperlipidemia40.040.80.92
Smoking62.770.40.32
Symptom onset to reflow time (h)6.1 ± 4.97.8 ± 6.30.06
Incidence of pre-infarction angina (%)44.042.30.83
Killip class (I/II/III)64/9/268/3/00.03
Hemodynamic data on admission
Systolic blood pressure (mm Hg)139 ± 25137 ± 290.66
Heart rate (beats/min)82 ± 2077 ± 160.12
Rate–pressure product11,579 ± 4,20310,732 ± 3,5580.20
Hemodynamic data after PCI
Systolic blood pressure (mm Hg)124 ± 23124 ± 250.98
Heart rate (beats/min)87 ± 1881 ± 120.04
Rate–pressure product10,834 ± 3,28610,133 ± 2,7780.17
ST-segment re-elevation (%)>49.326.80.005
Stent implantation (%)45.353.50.32
Anterior wall MI (%)66.760.60.44
TIMI flow grade on initial CAG (%)80.073.20.33
Good collateral channels*(%)29.330.00.93
WMS on admission14.8 ± 5.614.9 ± 5.60.94
ΔWMS3.7 ± 4.85.7 ± 4.30.01
Medication after AMI
ACE inhibitor (%)88.793.30.53
Beta-blocker (%)28.029.60.83

Abbreviations as in Table 1.

  • * Good collateral channels indicate collateral flow graded as 2 or 3. Data are presented as the mean value ± SD or number or percentage of patients.